Xenetic Biosciences Inc (XBIO)

May 31, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World

May 31, 2025

May 17, 2025

Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

May 17, 2025

May 17, 2025

Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World

May 17, 2025

May 14, 2025

Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 14, 2025

Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus

May 14, 2025

May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus

May 14, 2025

May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire

May 14, 2025

May 14, 2025

Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan

May 14, 2025

May 14, 2025

Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post

May 14, 2025

May 08, 2025

Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World

May 08, 2025

May 06, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com

May 06, 2025

May 05, 2025

Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView

May 05, 2025

May 04, 2025

Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire

May 04, 2025

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

May 01, 2025

Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World

May 01, 2025

Apr 28, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire

Apr 28, 2025

Apr 27, 2025

Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire

Apr 27, 2025

Apr 27, 2025

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

Xenetic Biosciences, Inc. to Present at BIO Investor Forum - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire

Apr 25, 2025